CRSP
CRISPR Therapeutics AG
NASDAQ: CRSP · Zug, Switzerland · Healthcare
$55.54-2.15 (-3.73%)Closed
Market Cap$4.12B
Cash$1.82Bmost recent
Runway21 mo$217.0M Q burn
P/E (TTM)—EPS $-7.85
52-Wk Range$33.16 – $76.78
Avg Volume2.4M3-month
Healthstable
Gene-editing company developing CRISPR/Cas9 therapies for hemoglobinopathies, oncology, and cardiovascular disease.
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$55.54-0.2%
Pipeline
Drug candidates sponsored by CRISPR Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 1 | CTX110 | B-cell Malignancy+3 more | Terminated | 2024-10-04past | 1 | |
| Phase 1 | Unnamed | Diabetes Mellitus+6 more | Recruiting | 2025-04past | 1 | |
| Phase 1 | CTX131 | Clear Cell Renal Cell Carcinoma+7 more | Completed | 2026-03-11past | 2 | |
| Phase 1 | CTX112 | B-cell Lymphoma+14 more | Recruiting | 2030-01 | 2 | |
| Phase 1 | Unnamed | Diabetes Mellitus+6 more | Completed | 2023-01-19past | 1 | |
| Phase 1 | CTX120 | Multiple Myeloma | Terminated | 2024-01-04past | 1 | |
| Phase 1 | CTX130 | T Cell Lymphoma+1 more | Terminated | 2024-10-08past | 2 | |
| Phase 1 | CTX310 | Cardiovascular+9 more | Recruiting | 2027-06 | 1 | |
| N/A | Unnamed | Hematologic Malignancy+1 more | Enrolling | 2038-08 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Gene editing · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.